Glenmark gets USFDA nod for generic high blood pressure drug

Drug firmGlenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator for its generic Diltiazem Hydrochloride extended release capsules used for treatment of high blood pressure.

The company has received final approval from the United States Food & Drug Administration (USFDA) for Diltiazem Hydrochloride extended-release capsules USP, in the strengths of 60 mg, 90 mg, and 120 mg, Glenmark said in a statement.

The product is a generic version of Biovail Laboratories Inc’s Cardizem SR extended-release capsules in the same strengths, it added.

The company has been granted a competitive generic therapy (CGT) designation for these capsules, therefore, with thisapproval, Glenmark is eligible for 180 days of CGT exclusivity upon commercial marketing, the statementsaid.

According to IQVIA sales data for the 12-month period ending January 2021, the Cardizem SR extended-release capsules, 60 mg, 90 mg, and 120 mg market (including brand and all available therapeutic equivalents) achieved annual sales of approximately USD 56.7 million, it added.

The company’s current portfolio consists of 170 products authorised for distribution in the US marketplace and 42 abbreviated new drug applications (ANDA’s) pending approval with the USFDA, Glenmark said.

Shares ofGlenmark Pharmaceuticals were trading at Rs464.45per scrip on BSE, up 0.98 per cent over previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor